Bloom A S, Dewey W L, Harris L S, Brosius K K
J Pharmacol Exp Ther. 1977 Feb;200(2):263-70.
The effects of (+/-)9-nor-9beta-hydroxyhexahydrocannabinol (beta-HHC) on tail-flick test activity and the accumulation of newly synthesized dopamine and norepinephrine were studied in the male albino mouse. The same parameters were also studied in naloxone-pretreated and morphine-tolerant mice. beta-HHC was about equipotent with morphine in the mouse tail-flick (ED50 = 7.12 mg/kg). The cannabinoid also produced dose-dependent increases in the accumulation of newly synthesized DA and NE. Pretreatment with 2 mg/kg of naloxone antagonized both the tail-flick activity and blocked the increases in catecholamine synthesis produced by beta-HHC. Cross-tolerance between beta-HHC and morphine did not exist in regard to either tail-flick activity or increased catecholamine synthesis. These studies suggest that beta-HHC may share some properties with the narcotic analgesics but that significant differences exist. Furthermore, these studies offer further evidence for the involvement of catecholamine containing neurons in the central mediation of the tail-flick response.
研究了（±）9-去甲-9β-羟基六氢大麻酚（β-HHC）对雄性白化小鼠甩尾试验活性以及新合成多巴胺和去甲肾上腺素积累的影响。还在纳洛酮预处理和吗啡耐受的小鼠中研究了相同参数。β-HHC在小鼠甩尾试验中与吗啡的效力相当（半数有效量=7.12毫克/千克）。该大麻素还使新合成的多巴胺和去甲肾上腺素的积累呈剂量依赖性增加。用2毫克/千克纳洛酮预处理可拮抗甩尾活性，并阻断β-HHC产生的儿茶酚胺合成增加。在甩尾活性或儿茶酚胺合成增加方面，β-HHC与吗啡之间不存在交叉耐受性。这些研究表明，β-HHC可能与麻醉性镇痛药有一些共同特性，但也存在显著差异。此外，这些研究为含儿茶酚胺的神经元参与甩尾反应的中枢介导提供了进一步证据。
